Company intelligence / Profile preview
Mucommune
North Carolina, United Statesmucommune.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Mucommune develops innovative therapies in women's reproductive health. Its lead program uses anti-sperm monoclonal antibodies delivered via intravaginal ring or dissolving tablets to provide non-hormonal contraception. Early clinical data with a first-generation antibody showed high potency; a second-generation molecule aims to improve efficacy and reduce dose/costs. Another pipeline product targets bacterial vaginosis with a non-antibiotic approach. The company has received over $12M in non-dilutive funding and plans IND filings for both products in 2024. Inhalon Biopharma was spun out of Mucommune in 2019 as a separate entity focused on respiratory diseases.
- Therapeutic areas
- Women's HealthInfectious Diseases
- Modalities
- Monoclonal antibodies (mAbs)Non-antibiotic therapeutics
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
03
Partnerships
Not explicitly listed, but Inhalon’s partnership with Celltrion mentioned as related news.
Beyond the preview
Go deeper on Mucommune.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mucommune.